Molecular Partners AG

Molecular Partners is a Swiss biotechnology company developing experimental cancer drugs. The company uses a technology platform called DARPin to design proteins that can attack cancer cells or train the body's immune system to fight cancer. Several of their drug candidates are in early-stage clinical trials testing treatments for solid tumors, blood cancers, and lung cancers. The company also partners with other organizations to combine their technology with radioactive compounds that can target and destroy tumors.